Thread What are the long term effects of taking hydroxycarbamide
The short version: the evidence retrieved does not answer the question of long-term effects of hydroxycarbamide in the general population. It mostly studies a different drug or a different disease.
The evidence you provided is a mix of studies on anagrelide (a different drug) , a single case report of platelet oscillations , a vaccine response study in myelofibrosis patients , and a trial in children with sickle cell anemia . None of these are designed to establish the long-term safety profile of hydroxycarbamide in adults with the conditions it is most commonly prescribed for, like polycythemia vera or essential thrombocythemia.
The TWiTCH trial in sickle cell children is the only randomized controlled trial here. It found that over 24 months, hydroxycarbamide was non-inferior to transfusions for preventing strokes, with more serious adverse events in the hydroxyurea arm (23 vs 10) . That is a short-term trade-off in a specific pediatric population, not a long-term safety picture for adults. The anagrelide study reports a 2% rate of acute myeloid leukemia over a median 12.5-year follow-up, but that is for a different drug, not hydroxycarbamide. The case report is a single patient observation, not population evidence.
The evidence retrieved does not contain a single long-term safety study of hydroxycarbamide in adults with myeloproliferative neoplasms. The gap itself matters. The question of cumulative toxicity, leukemogenic risk, or impact on survival over decades is simply not answered by the studies provided.
My call: the evidence retrieved does not address the long-term effects of hydroxycarbamide in the populations where it is most used. Confidence: not clear.
This page answers the follow-up:
Question explored with the scientific record
What long-term side effects are seen in adults with polycythemia vera or ET?
The short version: the evidence retrieved does not contain a single study on long-term side effects of hydroxycarbamide in adults with polycythemia vera or essential thrombocythemia.
The evidence you provided is almost entirely off-topic. It covers skin toxicity from cancer drugs like cetuximab and erlotinib [3, 5, 6, 10, 11, 13, 14], radiation dermatitis [9, 12], methotrexate skin reactions [7], and anagrelide in essential thrombocythemia [2]. None of these answer the question about hydroxycarbamide in polycythemia vera or ET.
The one study that does involve hydroxycarbamide is the BABY HUG trial in children with sickle cell anemia [1]. That is a different drug, a different disease, and a different population. It found no significant difference in spleen or kidney function over 24 months compared to placebo [1], but that tells you nothing about chronic toxicity over years in adults with myeloproliferative neoplasms. The anagrelide study [2] reports a 2% rate of acute myeloid leukemia over a median 12.5-year follow-up, but that is for a different drug entirely.
The gap is the story. No long-term safety data for hydroxycarbamide in the populations where it is most prescribed was provided. The question of leukemogenic risk, cumulative toxicity, or impact on survival over decades remains unanswered by this evidence.
My call: the evidence retrieved does not address the long-term side effects of hydroxycarbamide in adults with polycythemia vera or essential thrombocythemia. Confidence: not clear.
Sources examined 14
-
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)
The BABY HUG trial demonstrated that hydroxycarbamide therapy in very young children with sickle-cell anaemia significantly reduced pain and dactylitis events, while showing no significant differences in primary endpoints of splenic and renal function compared to placebo.
DOI: 10.1016/S0140-6736(11)60355-3 -
Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25 years by the “Ph1‐negative Myeloproliferative Neoplasms Latium Group”
In a retrospective cohort of 150 ET patients, anagrelide achieved high response rates (85.4%) with a low rate of major thrombotic and bleeding events, and was preferentially used in younger patients, particularly as second/third-line after 2004.
DOI: 10.1111/ejh.13454 -
Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials
This meta-analysis of 65 randomized controlled trials involving 25,994 cancer patients reveals that anti-EGFR monoclonal antibodies significantly increase the risk of all-grade and high-grade skin toxicities, particularly rash, hand-foot syndrome, dry skin, and oral mucositis, w…
DOI: 10.1007/s00280-018-3644-2 -
1009 IS SKIN TOXICITY A PREDICTOR OF BETTER SURVIVAL OF PATIENTS WITH HCC TREATED WITH SORAFENIB?
This study investigates the relationship between skin toxicity induced by Sorafenib treatment and survival outcomes in patients with advanced hepatocellular carcinoma (HCC), finding that skin toxicity is a significant predictor of improved survival.
DOI: 10.1016/s0168-8278(12)61021-6 -
Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy
This study investigates the relationship between skin toxicity severity and clinical outcomes, including progression-free survival and overall survival, in patients with metastatic colorectal cancer receiving panitumumab monotherapy, revealing that greater skin toxicity is assoc…
DOI: 10.1002/cncr.24088 -
Skin Rash During Cetuximab Treatment in Advanced Colorectal Cancer: is Age a Clinical Predictor?
This study evaluates the intensity and duration of skin rash in young and elderly patients with advanced colorectal cancer treated with cetuximab, finding that age is not a significant predictor of skin toxicity.
DOI: 10.1007/s12029-013-9485-7 -
Low-dose methotrexate-induced skin toxicity: Keratinocyte dystrophy as a histologic marker
This study investigates the histologic features of skin toxicity induced by low-dose methotrexate in five patients, highlighting keratinocyte dystrophy as a potential diagnostic marker.
DOI: 10.1016/j.jaad.2015.06.015 -
Impact of Skin Toxicities Associated with Targeted Cancer Therapies on Body Image: A Prospective Study
This prospective study investigates the impact of skin toxicities from targeted cancer therapies on body image and psychosocial well-being, finding that while most patients experience skin issues, their body satisfaction remains stable and is often linked to pre-existing body im…
DOI: 10.1007/s40261-015-0373-8 -
EP-1189: Hypofractionated RT with or without boost in breast cancer: an institutional analysis of toxicity
Randomized controlled trial in 52 breast cancer patients undergoing radiotherapy after breast-conserving surgery shows that a thymine-lysine-hyaluronic acid–based cream (Repalysyal) applied twice daily significantly reduces acute radiation-induced skin toxicity compared with sta…
DOI: 10.1016/s0167-8140(16)32439-2 -
Evaluation of Prophylactic Tetracyclines Use in Cetuximab Chemotherapy for Head and Neck Cancer
A retrospective evaluation of prophylactic tetracyclines in cetuximab-containing therapy for head and neck cancer (n=37) found no difference in overall skin toxicities versus Japanese Phase II/EXTREME benchmarks, but a lower rate of grade 3 or higher toxicities compared with EXT…
DOI: 10.1093/annonc/mdt459.39 -
Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti‐EGFR‐based therapy?
A retrospective study of 104 advanced colorectal cancer patients treated with anti-EGFR antibodies assessed whether Fc gamma receptor polymorphisms (FccRIIa-H131R and FccRIIIa-V158F) and KRAS mutations predict treatment response and progression-free survival, finding KRAS mutati…
DOI: 10.1111/j.1349-7006.2010.01621.x -
The Time Interval From Conservative Breast Surgery to Breast Irradiation in Early-Stage Node-Negative Breast Cancer: 17-Year Follow-Up Results and Patterns of Recurrence
This study investigates the correlation between acute breast skin toxicity and various bra cup size measurements in patients undergoing radiation therapy for breast cancer, finding that traditional patient-reported cup sizes do not significantly correlate with toxicity outcomes.
DOI: 10.1016/j.ijrobp.2013.06.615 -
Safety Profile of Erlotinib: a Survey of Five Months
This study evaluates the adverse drug reactions (ADRs) associated with erlotinib in patients with non-small cell lung cancer, finding that skin toxicity and diarrhea are the most common side effects.
DOI: 10.2165/00002018-200629100-00156 -
Clinical Management of Cutaneous Toxicity of Anti-EGFR Agents
This study reviews the cutaneous toxicity associated with anti-EGFR agents, particularly focusing on the mechanisms, clinical manifestations, and management strategies for skin reactions observed in patients undergoing treatment for metastatic colorectal carcinoma.
DOI: 10.1177/17246008070221s407